Alliance for Pandemic Preparedness

May 19, 2021

Effectiveness of BNT162b2 MRNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Mortality Following COVID-19

Category:

Topic:

Keywords (Tags):

  • [Pre-print, not peer-reviewed] Even in the small percentage of vaccine recipients who develop symptomatic disease, vaccination with either the Pfizer-BionNTech vaccine or the Oxford-AztraZeneca vaccine conferred additional protection against death, according to analysis of data from England. Among adults aged ≥70 years with COVID-19, those vaccinated with 1 dose of the Pfizer-BioNTech vaccine, 1 dose of Oxford-AstraZeneca vaccine, and 2 doses of the Pfizer-BioNTech vaccine had a 44%, 55%, and 69% reduced risk of death, respectively, compared to unvaccinated adults according to an analysis of 48,096 cases with at least 28 days of follow-up. The protection from death conferred by vaccines is additional to conferred protection against COVID-19. Reductions in risk were similar by age group; however, care home residents had a smaller reduction in risk of death after 1 dose of the Pfizer-BioNTech vaccine compared to non-care home residents (13% vs 52%), but a larger reduction in risk of death after 1 dose of the Oxford-AstraZeneca vaccine (63% vs 48%).

Bernal et al. (May 18, 2021). Effectiveness of BNT162b2 MRNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Mortality Following COVID-19. Pre-print downloaded May 19 from https://doi.org/10.1101/2021.05.14.21257218